ANXA1 and cancer: This is particularly important in cancers such as breast, bladder, gastric and leukaemia, whereby it has been discovered that ANXA1 can behave as both a tumour suppressor and oncogene (reviewed in [102,103]), with differentiated levels of expression dependent on tissue and cell type, emphasising the need for personalised medicine in the future.